Syndax Pharmaceuticals
SNDX
123 hedge funds and large institutions have $938M invested in Syndax Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 41 reducing their positions, and 12 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
130% more call options, than puts
Call options by funds: $894K | Put options by funds: $389K
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
9% more capital invested
Capital invested by funds: $862M → $938M (+$75.8M)
7% more funds holding
Funds holding: 115 → 123 (+8)
7% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 41
3.16% less ownership
Funds ownership: 104.08% → 100.92% (-3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.71M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$6.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.25M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$6.22M |
| 5 |
Barclays
London,
United Kingdom
|
+$5.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$24.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$17.8M |
| 3 |
Goldman Sachs
New York
|
-$12.6M |
| 4 |
HM
HealthCor Management
New York
|
-$8.94M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$5M |
SNDX Hedge Fund Activity: Q3 2021 in Review
123 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2021, worth a combined $938M — up 8.8% from $862M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new SNDX positions and 12 closed out — a net gain of 8 holders — while 38 added to existing stakes and 41 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $7.71M. The largest seller was Avoro Capital Advisors, cutting an estimated $24.2M.
- 123 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2021, up from 115 in Q2 2021.
- Funds reported $938M of Syndax Pharmaceuticals stock for Q3 2021, up 8.8% quarter-over-quarter.
- 20 funds opened new Syndax Pharmaceuticals positions in Q3 2021 and 12 closed out, a net change of +8 holders.
- The largest Syndax Pharmaceuticals buyer in Q3 2021 was Eventide Asset Management, an estimated $7.71M added.
- The largest Syndax Pharmaceuticals seller in Q3 2021 was Avoro Capital Advisors, an estimated $24.2M sold.
Based on aggregated 13F filings for Q3 2021.